Polypill treatment for cardiovascular disease provides high worth in low-income, underserved population
Polypill treatment for heart disease avoidance is of high worth in a low-income, underserved population, according to research study released in JAMA Cardiology
Ciaran N. Kohli-Lynch, Ph.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and coworkers simulated scientific and financial results of the Southern Community Cohort Study (SCCS) Polypill Trial from a healthcare sector viewpoint, embracing a time horizon of 10 years. In the base case analysis, polypill treatment was priced at $46...